Glimepirida Ciclum (Glimepiride)

Glimepirida Ciclum is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient.

• Improves glycemic control as part of a comprehensive diabetes care plan.
• Can be combined with metformin or other non‑insulin antidiabetic agents.
• May be used when a patient requires an oral agent that enhances endogenous insulin secretion.
• Typically prescribed after evaluating renal function and risk of hypoglycemia.
• May be considered in patients who have not achieved target HbA1c with lifestyle measures alone.

The safety profile of glimepiride includes both frequent, mild reactions and less common, potentially serious events.

Common

• Mild hypoglycemia, often presenting as shakiness or sweating.
• Nausea, stomach upset, or abdominal cramps.
• Headache or light‑headedness.
• Weight gain.
• Fatigue or general weakness.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reactions such as rash, itching, swelling, or difficulty breathing.
• Significant liver enzyme elevations or rare blood‑cell abnormalities.

Before starting Glimepirida Ciclum, healthcare providers should assess several clinical factors to minimize risks.

• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Review history of hypoglycemia; patients with prior episodes require close monitoring.
• Use cautiously in elderly patients due to increased sensitivity to insulin secretagogues.
• Avoid use during pregnancy or breastfeeding unless benefits outweigh risks, as safety data are limited.
• Counsel patients on recognizing and managing low blood sugar symptoms.
• Consider cardiovascular status, as sulfonylureas may affect heart ischemia risk.

Glimepirida Ciclum can interact with other medicines, altering blood glucose control or increasing adverse effects.

Avoid

• Other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride plasma levels.
• Disulfiram, due to reported enhanced hypoglycemic response.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose and affect fluid balance.
• Anticoagulants such as warfarin, where glimepiride may alter INR monitoring.